This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MTCR Metacrine (MTCR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Metacrine Stock (NASDAQ:MTCR) Get Metacrine alerts:Sign Up Key Stats Today's Range$0.58▼$0.5950-Day Range$0.55▼$0.5952-Week Range$0.30▼$0.59Volume83,889 shsAverage Volume225,834 shsMarket Capitalization$24.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Read More Receive MTCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metacrine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTCR Stock News HeadlinesU.S. sending powerful defense system to Israel, deepening its involvement in the conflictNovember 11, 2024 | nbcnews.comNorth Korea: 6 Experts on How We Can Solve the ProblemOctober 25, 2024 | time.comTCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really investing in this coin.September 16 at 2:00 AM | Crypto 101 Media (Ad)'Iran made a big mistake': Israel promises revenge after missile attackOctober 4, 2024 | usatoday.comUkraine summons Iranian diplomat as Tehran denies missile transfer to RussiaSeptember 11, 2024 | reuters.comRussia strikes Ukraine's power grid in 'most massive' attack of warAugust 28, 2024 | reuters.comCuban regime’s reported return to meddling in US elections a ‘badge of honor’ for targeted criticsAugust 1, 2024 | foxnews.comUS says China is boosting Russia's war machine in UkraineApril 17, 2024 | reuters.comSee More Headlines MTCR Stock Analysis - Frequently Asked Questions How were Metacrine's earnings last quarter? Metacrine, Inc. (NASDAQ:MTCR) issued its quarterly earnings data on Thursday, May, 13th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.06. When did Metacrine IPO? Metacrine (MTCR) raised $84 million in an IPO on Wednesday, September 16th 2020. The company issued 6,500,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager. What other stocks do shareholders of Metacrine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Metacrine investors own include Oncobiologics (OTLK), Plug Power (PLUG), Advanced Micro Devices (AMD), Salesforce (CRM), Fisker (FSR), Micron Technology (MU) and 9 Meters Biopharma (NMTR). Company Calendar Last Earnings5/13/2021Today9/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MTCR CIK1634379 Webwww.metacrine.com Phone858-369-7800FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-84.88% Return on Assets-59.33% Debt Debt-to-Equity Ratio0.34 Current Ratio12.15 Quick Ratio12.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.36 per share Price / Book0.43Miscellaneous Outstanding Shares42,570,000Free Float36,695,000Market Cap$24.75 million OptionableNot Optionable Beta-0.73 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:MTCR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metacrine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metacrine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
